Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 26, 2023 1:11pm
68 Views
Post# 35248117

RE:market CRAZYNESS

RE:market CRAZYNESS
bluemoons20 wrote: What is this  It  goes  up  and then someone dumps at below  market???

On a  penny  stock??

This is nuts!!

GLTA


It is more like market BS !  
Down we go.  Not sure if this announcement has anything to do with it but I am sure the never ending dilution doesn't help;
From Stockwatch today:

RepliCel ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND GRANT OF STOCK OPTIONS

RepliCel Life Sciences Inc. has arranged a non-brokered private placement financing of up to 10.5 million units at a price of 10 cents per unit for gross proceeds of up to $1.05-million. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company at a price of 20 cents per share for a period of four years from closing of the offering. The offering is subject to the approval of the TSX Venture Exchange. Insiders may participate in the offering.

Finders' fees may be payable in connection with the offering in accordance with the policies of the exchange.

All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after closing of the offering. Completion of the offering is subject to the approval of the exchange. Any participation by insiders in the offering will constitute a related party transaction under Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions but is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101.

The aggregate gross proceeds from the sale of the offering will be used for general working capital.

The company also announces that it has granted an aggregate of 1.87 million stock options to certain directors, officers, employees and consultants for the purchase of up to 1.87 million common shares of the company pursuant to its 2014 stock option plan. Each option is exercisable for a period of three years from Jan. 26, 2023, at a price of 12 cents per common share. A total of 1.27 million of these options vest immediately and 600,000 of these options vest as to 50 per cent on Jan. 26, 2023, 25 per cent on Dec. 31, 2023, and 25 per cent on June 30, 2024. 
<< Previous
Bullboard Posts
Next >>